Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Reyvow (Lasmiditan) is a prescription medication approved for the acute treatment of migraine with or without aura in adults. It belongs to a class of drugs called ditans, which work differently from triptans. Reyvow is taken as a single tablet at the onset of a migraine attack. It is a Schedule V controlled substance, meaning it has a low potential for misuse. Importantly, Eli Lilly has announced that Reyvow is being permanently discontinued, with U.S. distribution ending May 31, 2026.
Reyvow selectively activates serotonin 5-HT1F receptors in the brain. By targeting these receptors, it inhibits neuronal firing and reduces the release of neuropeptides involved in the trigeminal pain pathway — the system responsible for migraine pain. Unlike triptans (such as Sumatriptan), Reyvow does not cause vasoconstriction (narrowing of blood vessels), which made it a valuable option for migraine patients with cardiovascular risk factors. However, it can cause significant dizziness and sedation, and patients must not drive or operate machinery for at least 8 hours after taking a dose.
Reyvow (Lasmiditan) has been permanently discontinued by Eli Lilly. The manufacturer announced a voluntary global discontinuation in late 2025, and U.S. distribution is expected to end by May 31, 2026. This is a business decision — not related to safety or quality concerns. While some pharmacies may still have remaining inventory, supply is rapidly declining. Patients currently taking Reyvow should work with their prescriber to transition to an alternative acute migraine treatment as soon as possible. Medfinder can help you locate any remaining stock near you.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Reyvow is most commonly prescribed by neurologists and headache specialists, but it can also be prescribed by primary care physicians, internists, and family medicine doctors. If you currently take Reyvow and need help transitioning to an alternative before the discontinuation date, your prescriber is the best place to start.
Yes. Reyvow is classified as a Schedule V (C-V) controlled substance by the DEA, the lowest level of controlled substance scheduling. This classification is due to Reyvow's potential to cause feelings of euphoria and sedation. Schedule V status means prescriptions may have additional restrictions depending on your state, including limits on refills and requirements for in-person prescriber visits.
Reyvow was a first-in-class migraine treatment that offered a unique non-vasoconstrictive option for patients who couldn't safely use triptans. Unfortunately, Eli Lilly's decision to permanently discontinue the drug means patients need to act now. If you're currently taking Reyvow, talk to your doctor about switching to an alternative such as Ubrelvy, Nurtec ODT, or Zavzpret before remaining pharmacy stock runs out. Use Medfinder to locate any remaining Reyvow inventory near you while supplies last.
%2C%20Color%3DOriginal.png)
